Additional file 3: Figure S1. of Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro
Endometrial cancer cell lines in which synergism was observed to the combination of pictilisib (PI3K), apitolisib (PI3K/mTOR), and cobimetinib (MEK) inhibitors. a) Eight cell lines in which synergism was observed to the combination of PI3K and MEK inhibition. b) Eight cell lines in which synergism was observed to the combination of PI3K/mTOR and MEK inhibition. (XLSX 158Â kb
